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to all major pharmaceutical companies with drugs 
used in affective and related disorders, and reports 
investigator-initiated studies funded by Astra 
Zeneca, Eli Lilly, Lundbeck, and Wyeth.
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should not surprise or disappoint 
us that they might not in bipolar 
depression. In our data, participants 
treated with minocycline ended 
with marginally higher scores on 
the 17-item and 24-item HAMD 
scales than those not so exposed; 
this result was nominally statistically 
significant on two-tailed tests, in one 
case surviving Bonferroni correction. 
This finding is unimportant clinically 
and possibly due to chance. It could 
be a signal that microglial activation, 
if it occurs in bipolar disorder, is 
protective rather than pathogenic. 
This notion is increasingly recognised 
in neurodegenerative disorders and 
different from proposed inflammatory 
mechanisms of unipolar depression.5 
In conclusion, we believe the overall 
negative effect of minocycline, which 
opposed our a priori hypothesis, is a 
true negative result and not due to the 
methodological issues raised by Berk 
and colleagues.
We agree that our study “might 
not be the last word on the potential 
role of anti-inflammatory drugs in 
the treatment of bipolar depression”. 
We simply argue that further trials 
like ours are not justified until we 
have stronger evidence for immune 
activation in bipolar depression and a 
set of specific and sensitive biomarkers 
for detecting it beyond a plasma 
cytokine level.
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We agree that having a reference 
drug in clinical trials is desirable. 
However, our colleagues acknowledge 
the practical difficulties and the many 
design issues with active compar-
ator trials. In addition, for bipolar 
depression there is no established 
effective reference therapy.2 Bipolar 
depression is typically resistant to 
treatment, which was one of the 
rationales for our study.
We observed a marked decline in 
Hamilton Depression Rating Scale 
(HAMD) scores overall, from 24·5–25·2 
to 11·3–12·8 with a mean final 
score of 12 (SD 7).3 However, many 
participants had final scores greater 
than 18 (which was the inclusion 
severity criterion) and 186 (70%) 
of 266 did not remit.3 Remission 
rates were sufficiently higher in 
those receiving celecoxib to just miss 
Bonferroni-corrected significance.3 
This finding might indeed indicate 
that inflammatory factors play a weak 
role in the overall group or stronger 
effects in subgroups. Nevertheless, our 
results suggest that there was room 
for improvement that the treatments 
did not fill.
The idea that bipolar depression is 
too heterogeneous for a one-target 
therapy to show benefit seems an 
unwarranted counsel of despair. 
Single action therapies do work 
for heterogeneous disorders such 
as major depression,4 suggesting 
common pathways. Furthermore, 
inflammation is not a unitary target; 
it is multidimensional to the point of 
defying agreed definition. Minocycline 
and celecoxib have different cellular 
and molecular targets. We tested 
them alone and in combination. Our 
design was a multitargeted attempt 
to block the inflammatory pathways 
implicated in mood disorders.
Bipolar depression does not 
respond well to SSRIs, which suggests 
that it has an underlying unity 
and a pathogenesis distinct from 
unipolar depression. Although anti-
inflammatory drugs show promise 
in treating unipolar depression, it 
The 341 737 ways of 
qualifying for the 
melancholic specifier
There is considerable symptom 
heterogeneity in major depressive 
disorder. Here,  we show that 
melancholia, which is a specifier for 
major depressive disorder in the 
DSM-5 and is meant to identify a 
more homogeneous subgrouping of 
individuals, features over ten times 
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not replicate these findings.4,5 These 
more recent results are not surprising 
if specifiers are more heterogeneous 
than the higher-order category of 
major depressive disorder, which is 
already highly heterogenous. Further, 
specifiers are common, often overlap, 
and might not be temporally stable, 
raising other problems of validity.3,5
The pronounced heterogeneity 
of melancholia as a specifier in 
the DSM-5 challenges the idea 
that melancholia identifies a more 
homogeneous group of patients. 
This finding calls for investigations 
that extend our analyses to other 
depression specifiers, especially those 
that add a polythetic symptom set, 
and also to specifiers of other mental 
disorders. Further, these results call 
for research into whether the large 
number of unique profiles created by 
the specifier for melancholia can be 
seen in patients. Given that unique 
profiles are observed in patients 
with major depressive disorder,1 
it is not unlikely that this is true 
for specifiers.
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is one of the oldest, linked to 
conceptualisations of depression from 
centuries ago, and is the focus of this 
letter.
Depression with melancholic 
features was first operationally 
defined in the DSM-III ,  and 
critically discussed at the time of 
its implementation in the 1980s. 
Nowadays, the debate about the 
validity of melancholia is ongoing 
and unresolved. 3 The DSM-5 
oper ationalises melancholia by 
eight symptom criteria that overlap in 
part with major depressive disorder, 
and additional symptoms, such as 
lack of reactivity to stimuli that are 
usually pleasurable, profound despair, 
and waking up early in the morning. 
A diagnosis of melancholia requires 
the presence of major depressive 
disorder, anhedonia or absence of 
mood reactivity, and at least three 
of the criteria for the melancholia 
specifier.
Although the DSM-5 states 
that specifiers can help to identify 
homogeneous subgroupings of 
individuals, this seems highly unlikely. 
Similar to major depressive disorder, 
we calculated all of the unique 
symptom profiles for melancholia, 
without and with splitting two 
qualitatively different compounds 
into subsymptoms. This calculation 
leads to between 10 999 and 
341 737 unique profiles; over an order 
of magnitude more profiles than 
we identified for major depressive 
disorder (227–10 377 profiles). Given 
that major depressive disorder is 
required to qualify for the melancholic 
specifier, the increased heterogeneity 
of melancholia is not surprising 
mathematically, but contrasts with 
the intuitions that are often held 
about the term specifier.
Evidence for the validity or clinical 
use of depression specifiers is weak.2,3 
Although studies initially reported 
that specific antidepressants are more 
efficacious than others for treating 
particular specifiers studies done in 
larger samples in the past decade did 
more heterogeneity than does major 
depressive disorder.
There are over 280 ways to 
measure depression, which capture 
considerably different symptom 
content, with seven common 
scales measuring over 50 disparate 
symptoms. The DSM-5 criteria for 
major depressive disorder require a 
person to have at least five of nine 
symptoms, at least one of which has 
to be either sad mood or anhedonia. 
All symptom criteria, apart from sad 
mood, are compounds that contain 
“or” in the description, such as loss 
of interest or pleasure, allowing 
for qualitatively different ways 
to qualify for the same criterion. 
If the subsymptoms are ignored, 
227 unique ways exist to qualify for 
major depressive disorder (appendix). 
Considering important qualitative 
differences for six of the compounds, 
such as loss of interest or pleasure 
and hypersomnia or insomnia, 
leads to 10 377 unique symptom 
profiles. Although this exercise is 
only mathematical, empirical work 
has shown that many of these 
profiles can be seen in patients with 
depression. For instance, we identified 
1030 unique profiles in 3703 patients 
with depression from the STAR*D 
study,1 83·9% (864 of 1030) of 
which were reported in five or fewer 
participants.
To tackle this widely known 
heterogeneity in the presentation 
of major depressive disorder, clinical 
researchers use subtypes or specifiers. 
Although these two terms are often 
used interchangeably, the DSM-5 
differentiates between subtypes 
(which are mutually exclusive) and 
specifiers (which are non-exclusive). In 
the past century, dozens of depression 
subtypes have been proposed and 
discarded, such as endogenous 
depression, introjective depression, 
and anaclitic depression.2 The DSM-5 
contains five symptom specifiers 
for depression: psychotic, catatonic, 
atypical, anxious, and melancholic. 
Of these specifiers, melancholia 
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